(Q33339739)

25 July 2017

title

Drug-induced and drug-dependent immune thrombocytopenias (English)

1 reference

25 July 2017

1 reference

4

Kiefel V

1 reference

25 July 2017

Greinacher A

1

1 reference

25 July 2017

Eichler P

series ordinal

2

1 reference

25 July 2017

Lubenow N

series ordinal

3

1 reference

25 July 2017

publication date

1 September 2001

1 reference

Reviews in Clinical and Experimental Hematology

25 July 2017

published in

1 reference

25 July 2017

volume

5

1 reference

25 July 2017

issue

3

1 reference

25 July 2017

page(s)

166-200; discussion 311-2

1 reference

Neutropenia and anaemia due to carbimazole-dependent antibodies

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Arterial Embolism Occurring During Systemic Heparin Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

The effect of molecular weight on heparin binding to platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Effect of Heparin and Heparin Fractions on Platelet Aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Heparin-induced platelet aggregation. II. Dose/response relationships for two low molecular weight heparin fractions (CY 216 and CY 222).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Heparin-induced platelet aggregation in anorexia nervosa and in severe peripheral vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Platelets of patients with peripheral arterial disease are hypersensitive to heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Antigen Generation in Heparin-Associated Thrombocytopenia: The Nonimmunologic Type and the Immunologic Type Are Closely Linked in Their Pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

The multiple complexes formed by the interaction of platelet factor 4 with heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Temporal aspects of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

A 14-year study of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Heparin-induced thrombocytopaenia complicated by bilateral adrenal haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Fatal cerebral venous sinus thrombosis in heparin-induced thrombotic thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Neurological complications in heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Pseudopulmonary embolism: acute respiratory distress in the syndrome of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Life-threatening anaphylactic reaction following parathyroidectomy in a dialysis patient with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Very low platelet counts in post-transfusion purpura falsely diagnosed as heparin-induced thrombocytopenia. Report of four cases and review of literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Potentials risks in drug prevention of thrombosis--low-molecular-weight heparin versus standard heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Heparin binding to platelet factor-4. An NMR and site-directed mutagenesis study: arginine residues are crucial for binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Investigation of a platelet factor 4 polymorphism on the immune response in patients with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

The epitope specificity of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Mode of interaction between platelet factor 4 and heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Synthesis of thrombin-inhibiting heparin mimetics without side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Platelet binding of IgG from patients with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Activation of platelets by sera containing IgG1 heparin-dependent antibodies: an explanation for the predominance of the Fc gammaRIIa "low responder" (his131) gene in patients with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Neutrophil attractant protein-1-immunoglobulin G immune complexes and free anti-NAP-1 antibody in normal human serum

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Cytokines and autoantibodies to cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Molecular basis for a polymorphism of human Fc gamma receptor II (CD32)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Single amino acid mutation of Fc gamma receptor is associated with the development of heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Immune endothelial-cell injury in heparin-associated thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Heparin‐induced thrombocytopenia: an improved method of detection based on lumi‐aggregometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Different platelet specificities of heparin-dependent platelet aggregating factors in heparin-associated immune thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Heparin-induced thrombocytopenia: laboratory investigation and confirmation of diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Danaparoid in the prevention of thromboembolic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Thrombosis during the use of the heparinoid Organon 10172 in a patient with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Development of hirudin as an antithrombotic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Recombinant hirudin (HBW 023): biological data of ten patients with severe venous thrombo-embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

The mechanism of activation of bovine prothrombin by an activator isolated from Echis carinatus venon and characterization of the new active intermediates

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

cDNA cloning and deduced amino acid sequence of prothrombin activator (ecarin) from Kenyan Echis carinatus venom

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Anticoagulation in patients with heparin-induced thrombocytopenia type II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Successful thrombolysis of right atrial and ventricle thrombi encircling a temporary pacemaker lead in a patient with heparin-induced thrombocytopenia type II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Heparin-induced thrombocytopenia as the cause of persistent bleeding after pacemaker implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Emergent cardiopulmonary bypass in five patients with heparin-induced thrombocytopenia type II employing recombinant hirudin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

A comparison between the use of recombinant hirudin and heparin during hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

The use of a low molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin dependent thrombocytopenia and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Pregnancy complicated by heparin associated thrombocytopenia: management by a prospectively in vitro selected heparinoid (Org 10172).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Images in cardiovascular medicine: pseudothrombocytopenia after abciximab (ReoPro) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Images in cardiovascular medicine. Abciximab-associated pseudothrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Drug-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Glycoprotein IIb/IIIa antagonists: potential induction and detection of drug-dependent antiplatelet antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Demonstration of an immune-mediated mechanism of penicillin-induced neutropenia and thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Red cell and platelet-bound IgG penicillin antibodies in a patient with thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Drug-Antibody-Platelet Interaction in Quinine- and Quinidine-induced Thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Metabolite-specific (IgG) and drug-specific antibodies (IgG, IgM) in two cases of trimethoprim-sulfamethoxazole-induced immune thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Fab-mediated binding of drug-dependent antibodies to platelets in quinidine- and quinine-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Binding of quinine- and quinidine-dependent drug antibodies to platelets is mediated by the Fab domain of the immunoglobulin G and is not Fc dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Absence of the platelet receptor for drug-dependent antibodies in the Bernard-Soulier syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Studies on quinine- and quinidine-dependent antibodies against platelets and their reaction with platelets in the Bernard-Soulier syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Drug-induced thrombocytopenia: a systematic review of published case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Immune thrombocytopenia due to a metabolite of para-aminosalicylic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Immune Thrombocytopenia Due to a Drug Metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Immune thrombocytopenia associated with hemorrhagic diathesis due to ibuprofen administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Detection of drug-dependent, platelet-reactive antibodies by antigen-capture ELISA and flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

The MAIPA assay and its applications in immunohaematology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

Thrombocytopenia associated with gold therapy: a drug-induced autoimmune disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2001.00041.X

10.1046/J.1468-0734.2001.00041.X

21 January 2018

Identifiers

DOI

1 reference

25 July 2017

1 reference